

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Spark Blue(TM) 550 anti-human CD3

RRID:AB_2819985

Type: Antibody

Proper Citation

BioLegend Cat# 344852, RRID:AB_2819985

Antibody Information

URL: http://antibodyregistry.org/AB_2819985

Proper Citation: BioLegend Cat# 344852, RRID:AB_2819985

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Spark Blue(TM) 550 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone SK7

Antibody ID: AB_2819985

Vendor: BioLegend

Catalog Number: 344852

Alternative Catalog Numbers: 344851

Record Creation Time: 20250820T025540+0000

Record Last Update: 20250820T145338+0000

Ratings and Alerts

No rating or validation information has been found for Spark Blue(TM) 550 anti-human CD3.

No alerts have been found for Spark Blue(TM) 550 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Forconi CS, et al. (2025) T follicular helper cell profiles differ by malaria antigen and for children compared to adults. bioRxiv : the preprint server for biology.

Forconi CS, et al. (2025) T-follicular helper cell profiles differ by malaria antigen and for children compared to adults. eLife, 13.

Salgia NJ, et al. (2025) Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma. Cancer cell.

Demetriou P, et al. (2025) CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated. iScience, 28(12), 113977.

Schulenberg S, et al. (2025) Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial. iScience, 28(11), 113680.

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer cell, 42(9), 1582.

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity, 57(9), 2232.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell, 187(16), 4336.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell reports, 38(2), 110235.

Asplund Högelin K, et al. (2021) Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. iScience, 24(9), 103078.

Cillo AR, et al. (2021) People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden. Cell reports.

Medicine, 2(12), 100476.